Meloxicam SBEβCD Inclusion Complex Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility leading to reduced bioavailability and slow onset of pain relief, necessitating a method to enhance its solubility and absorption.
Innovation Solution
A dosage form combining meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and a bicarbonate, forming an inclusion complex to increase solubility and bioavailability, and when paired with rizatriptan, provides rapid and sustained pain relief for migraine treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is used as a conventional NSAID, then it provides anti-inflammatory and analgesic activities, but it has poor aqueous solubility which reduces bioavailability and slows onset of pain relief
Solution Approach 1:
The patent uses cyclodextrins as intermediary carriers to solubilize meloxicam. The cyclodextrin molecules form inclusion complexes with meloxicam, where the hydrophobic interior of the cyclodextrin cavity accommodates the meloxicam molecule while the hydrophilic exterior interacts with aqueous media, thereby enhancing solubility and bioavailability without altering the parent drug molecule
Solution Approach 2:
The invention creates a composite pharmaceutical system combining meloxicam with cyclodextrin derivatives (such as sulfobutyl ether β-cyclodextrin). This composite approach integrates the therapeutic properties of meloxicam with the solubilizing capabilities of cyclodextrins, resulting in a formulation that maintains drug efficacy while overcoming solubility limitations
2Speed
If meloxicam is administered to achieve therapeutic effects, then it provides pain relief, but the onset of pain relief is slow due to poor solubility
Solution Approach 1:
Cyclodextrins serve as mediators that facilitate rapid dissolution and absorption of meloxicam. By pre-complexing meloxicam with cyclodextrins in the formulation, the drug is already in a solubilized state upon administration, eliminating the slow dissolution step and enabling faster onset of therapeutic action
Solution Approach 2:
The invention alters the physical-chemical parameters of meloxicam by forming inclusion complexes. This changes the apparent solubility, dissolution rate, and absorption kinetics of the drug, transforming it from a poorly soluble compound with slow onset to a rapidly dissolving formulation with fast onset of action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly enhances meloxicam's bioavailability and absorption, leading to rapid and sustained pain relief in migraine patients with a history of inadequate response to prior treatments, reducing the need for rescue medication and improving treatment outcomes.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
cyclodextrin compounds are also known to aggregate around a drug in a micelle-type structure
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.